Mutation and expression analysis of LZTS1 in ovarian cancer.
LZTS1 has been shown to have tumour suppressor activities against prostate and breast cancer and is located within a region of frequent loss of heterozygosity (LOH) at 8p22 in ovarian cancer. We have analysed the expression of LZTS1 in ovarian cancer and found no evidence of loss of expression relative to normal ovarian surface epithelial cells. We have also analysed the coding region of the LZTS1 gene in 87 primary ovarian adenocarcinomas by DHPLC and detected a single silent somatic mutation. These data indicate that LZTS1 is not the target of LOH at 8p22 in ovarian cancer.
Arnold
Jeremy M
JM
Queensland Institute of Medical Research, P.O. Box Royal Brisbane Hospital, Herston, Qld 4029, Australia. jeremya@qimr.edu.au
Choong
David Y H
DY
Lai
John
J
Campbell
Ian G
IG
Chenevix-Trench
Georgia
G
D000230:Adenocarcinoma / Q000235:genetics*; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D006801:Humans; D019656:Loss of Heterozygosity; D009154:Mutation; D010051:Ovarian Neoplasms / Q000235:genetics*; D010053:Ovary / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D025521:Tumor Suppressor Proteins / Q000235:genetics*
D004268:DNA-Binding Proteins; C118711:LZTS1 protein, human; D025521:Tumor Suppressor Proteins